QQ客服 官方微博 反馈留言

浏览/检索结果: 共2条，第1-2条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Socinski, Mark A.;  Spira, Alexander I.;  Paz-Ares, Luis G.;  Reck, Martin;  Lu, Shun 收藏  |  浏览/下载：31/0  |  提交时间：2022/01/10 Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials 期刊论文 ONCOIMMUNOLOGY, 2018, 卷号: 7, 期号: 12 作者:  Huang, Qingyuan;  Zhang, Hua;  Hai, Josephine;  Socinski, Mark A.;  Lim, Eric 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 anti-PD-1  atezolizumab  immunotherapy  nivolumab  non-small cell lung cancer  pembrolizumab